Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Large Molecule Therapeutics

An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma

Rhonda C. Kines, Isabella Varsavsky, Sanghamitra Choudhary, Debaditya Bhattacharya, Sean Spring, Roger McLaughlin, Shin J. Kang, Hans E. Grossniklaus, Demetrios Vavvas, Stephen Monks, John R. MacDougall, Elisabet de los Pinos and John T. Schiller
Rhonda C. Kines
1Aura Biosciences, Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rkines@aurabiosciences.com
Isabella Varsavsky
1Aura Biosciences, Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanghamitra Choudhary
1Aura Biosciences, Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Debaditya Bhattacharya
1Aura Biosciences, Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sean Spring
1Aura Biosciences, Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger McLaughlin
1Aura Biosciences, Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shin J. Kang
2Emory Eye Center, Emory University, Atlanta, Georgia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans E. Grossniklaus
2Emory Eye Center, Emory University, Atlanta, Georgia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Demetrios Vavvas
3Angiogenesis Laboratory Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Monks
1Aura Biosciences, Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John R. MacDougall
1Aura Biosciences, Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabet de los Pinos
1Aura Biosciences, Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John T. Schiller
4Laboratory of Cellular Oncology, NCI, NIH, Bethesda, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-17-0953 Published February 2018
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Rapid HSPG-mediated tumor killing by AU-011. 92.1 cells were preplated at 2.5 × 104/500 μL in a 24-well plate and allowed to grow for 48 hours. A total of 7.5 μg/mL (300 pmol/L) of AU-011 was incubated for 1 hour ± 1 mg/mL heparin at 4°C and then added to the cells for 1 hour at 37°C. IR700 dye was also added in an amount equivalent to that which is conjugated to 300 pmol/L of AU-011. After 1 hour, cells were washed twice and then either kept in the dark or exposed to 25 J/cm2 of 690 nm light. Images were acquired within 15 minutes of light treatment.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    HSPG specificity of AU-011 activity. HeLa (A) or 92.1MEL (B) cells were combined at a 1:1 ratio with either CHO-K1 (gray bar) or pgsA-745 cells (white bar) and coincubated with AU-011 at 300 pmol/L for 1 hour at 4°C. Cells were washed and then exposed to 25 J/cm2 or kept in the dark (0 J/cm2). Prior to combining cell lines, human cell lines were incubated with CFSE, and hamster cell lines were incubated with CellTrace Violet to distinguish the populations for flow cytometry analysis (example of the analysis provided in Supplementary Fig. S5). Data are reported as % dead as determined by viability staining. Values plotted are the mean of two experiments performed in triplicate and error bars represent the SEM.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Dose-dependent AU-011 tumor killing in vivo. AU-011 was systemically administered to nude mice with subcutaneous 92.1 tumors (40–80 mm3). After 12 hours, animals were exposed to 25 or 50 J/cm2 690 nm light. Tumors were removed after 24 hours, homogenized, and viability measured by flow cytometry. Vehicle, n = 3; AU-011, n = 5. Data are representative of two experiments. Two-tailed Student t test: *, P = 0.0091; **, P = 0.0071.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Accumulation of AU-011 in 92.1MEL ocular tumors after intravitreal injection. A, SDS-PAGE of tumor lysates from samples used in confocal microscopy (see Supplementary Fig. S6A–S6F) and analyzed on Odyssey CLx imager at 700 nm. Two examples each of rabbit 92.1MEL tumor lysates 8 (rabbits 1.2 and 1.3) or 16 hours (rabbits 3.3 and 3.4) after intravitreal injection. The negative control received vehicle only (rabbit 6.2). The arrow indicates the predominant L1 protein in AU-011. B, Measurement of AU-011 levels in tumor tissue lysates. Each dot represents AU-011 levels measured in the tumor recovered from one animal.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    AU-011 anticancer activity in a rabbit orthotopic xenograft model of uveal melanoma. Panels show H&E-stained sections of tumor-bearing rabbit eyes from the vehicle (A), 50 μg (B), 20 μg (C), and 5 μg (D) treated cohorts 2 days after treatment. Higher magnifications shown on the right are demarcated by black boxes in the overview images on the left.

Tables

  • Figures
  • Additional Files
  • Table 1.

    Binding and potency EC50 values (pmol/L) of AU-011 on a panel of human tumor cell lines

    BindingKilling
    92.1MEL27.37 ± 1.38561.74 ± 2.142
    NCI-H460133.7 ± 50.9470.32 ± 28.25
    HeLa26.17 ± 3.13766.24 ± 2.708
    HSC-310.99 ± 1.11524.72 ± 0.918
    MCF-753.28 ± 6.51937.21 ± 4.58
    SK-MEL-211.74 ± 0.95625.24 ± 1.693
    SK-OV-323.2 ± 1.41437.86 ± 6.831
    T2441.12 ± 5.14260.1 ± 18.53
    • NOTE: Values represent mean pmol/L ± SEM, obtained from three experiments performed in triplicate.

Additional Files

  • Figures
  • Tables
  • Supplementary Data

    • Figures S1-S7 merged - Figure S1-video composites of real time AU-011 mediated killing of 92.1MEL cells; Figure S2-Killing and binding comparison of free IR700 dye to VLP conjugated IR700 (AU-011) on HeLa and 92.1MEL cells; Figure S3-Demonstration of both the AU-011 dose and light fluence required for AU-011 killing activity on HeLa and 92.1 cells; Figure S4-Examples of the AU-011 EC50 binding and killing curves using 8 tumor cell lines and contributing to values supplied in Table 1; Figure S5-Example of the flow cytometry gating strategy used to obtain the values plotted in the mixed cell experiment shown in Figure 2; Figure S6-Companion confocal images showing time course uptake of AU-011 in 92.1MEL tumors implanted in the eyes of rabbits and quantified in Figure 4; Figure S7-H&E staining of 92.1MEL tumors implanted in rabbit eyes showing dose response effect of AU-011 8-9 days post-treatment.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 17 (2)
February 2018
Volume 17, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma
Rhonda C. Kines, Isabella Varsavsky, Sanghamitra Choudhary, Debaditya Bhattacharya, Sean Spring, Roger McLaughlin, Shin J. Kang, Hans E. Grossniklaus, Demetrios Vavvas, Stephen Monks, John R. MacDougall, Elisabet de los Pinos and John T. Schiller
Mol Cancer Ther February 1 2018 (17) (2) 565-574; DOI: 10.1158/1535-7163.MCT-17-0953

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma
Rhonda C. Kines, Isabella Varsavsky, Sanghamitra Choudhary, Debaditya Bhattacharya, Sean Spring, Roger McLaughlin, Shin J. Kang, Hans E. Grossniklaus, Demetrios Vavvas, Stephen Monks, John R. MacDougall, Elisabet de los Pinos and John T. Schiller
Mol Cancer Ther February 1 2018 (17) (2) 565-574; DOI: 10.1158/1535-7163.MCT-17-0953
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Improved Activity of CF10 in Preclinical Colorectal Cancer Models
  • Activity of ABBV-085 in Osteosarcoma
  • Predicting In Vitro Pharmacology of CD3 Bispecific Antibody
Show more Large Molecule Therapeutics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement